Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Clinical oncology Jg. 19; H. 1; S. 37 - 50
Hauptverfasser:	Kraehenbuehl, Lukas, Weng, Chien-Huan, Eghbali, Shabnam, Wolchok, Jedd D, Merghoub, Taha
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Nature Publishing Group 01.01.2022
Schlagworte:	Adenosine BTLA protein Cancer Clinical trials CTLA-4 protein Glucose metabolism Humans Immune checkpoint Immune checkpoint inhibitors Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunologic Factors - metabolism Immunomodulation Immunomodulators Immunotherapy Immunotherapy - methods Lymphocytes Lymphocytes T Metabolism Neoplasms - therapy Patients PD-1 protein PD-L1 protein Receptor mechanisms Signal transduction T cell receptors Tumor necrosis factor Tumors
ISSN:	1759-4774, 1759-4782, 1759-4782
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!